Interested in new trials?
Get alerts for new trials in your area by subscribing now
Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
What is multiple sclerosis?
In MS, the immune system attacks myelin, the insulation around nerve fibers in the brain and spinal cord. Damaged spots, called lesions, slow or block nerve signals, which is why symptoms range from fatigue and numbness to vision problems and trouble walking. Symptoms and pace differ so much between people that MS is often called a disease with a thousand faces. It is not contagious, and it is not directly inherited. Worldwide about 2.9 million people live with MS, someone is diagnosed roughly every five minutes, and the average age at diagnosis is 32.
Research in this field carries one of the most striking findings in modern medicine: a 2022 study of more than 10 million US military members found that infection with the Epstein Barr virus, the common virus behind mononucleosis, raises MS risk 32 times, making it the leading suspected cause. Meanwhile treatment keeps expanding, with more than 20 approved disease modifying therapies, though the progressive forms still have almost none.
The types of MS, and why they matter for trials
- CIS (clinically isolated syndrome). A first episode of symptoms. Not everyone with CIS goes on to develop MS.
- Relapsing remitting MS (RRMS). Attacks of symptoms followed by recovery periods. About 85% of people start here, and most approved medicines were built for this form.
- Secondary progressive MS (SPMS). A phase after RRMS where disability gradually grows. When it advances without relapses, no approved therapy currently exists for it.
- Primary progressive MS (PPMS). Steady worsening from the start, in roughly 10 to 15% of people. One drug, ocrelizumab (Ocrevus), has been approved for it since 2017.
The practical point for trial seekers: almost every MS study names the type it enrolls, plus a disability score called EDSS. Knowing your type tells you at a glance which studies fit you, and the progressive forms are where researchers most need volunteers right now.
Types of multiple sclerosis clinical trials
Multiple sclerosis (MS) clinical trials encompass a range of studies, each targeting different aspects of this neurological condition. They range from exploring new medications and therapies aimed at managing symptoms and altering the disease's course, to prevention strategies and rehabilitation methods to enhance the quality of life for those affected.
Treatment trials
Treatment trials in MS focus on finding new medications or treatment strategies to manage the symptoms of MS. These include trials for drugs that can effectively manage symptoms of MS, reduce the frequency and severity of relapses, and slow the progression of the disease.
Prevention trials to delay or prevent MS progression
Prevention trials aim to identify strategies that could prevent MS or delay its progression in individuals who are at high risk or in the early stages of the disease. These studies might involve lifestyle changes, medications, or other interventions that could potentially prevent the onset or reduce the progression of MS.
Rehabilitation trials
Rehabilitation trials research ways to improve daily functioning and quality of life for those diagnosed with MS. These trials might test physical therapy programs, cognitive rehabilitation techniques, or novel assistive technologies designed to help manage the symptoms of MS.
Trials for emerging therapies
These trials explore the potential of new and emerging therapies in MS treatment, such as stem cell therapy, neuroprotective strategies, and novel immunotherapies. The goal is to find breakthrough treatments that can significantly alter the course of MS.
Who can participate in MS trials?
MS studies usually recruit around four things: your MS type (relapsing or progressive), your disability level measured by the EDSS score, your relapse history, and which disease modifying therapies you have already tried. Some studies enroll only newly diagnosed people, others focus on progressive MS, where the need is greatest. Observational studies often have the widest doors, including studies of people at the earliest stage of disease. Eligibility always varies by study.
Considering volunteering in a clinical trial? Explore our comprehensive guide to learn more about why people choose to volunteer and the impact you can make in advancing medical research. Discover the process of volunteering, what to consider before applying and the potential benefits and risks involved.
Do MS trial participants get paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to enroll in a clinical trial for multiple sclerosis
Enrolling in an MS clinical trial through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore Study Details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the Health Profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.